Trials / Completed
CompletedNCT02222506
Safety Evaluation of the KLOX BioPhotonic System in Diabetic Foot Ulcers
A Prospective Case Series Evaluating the Safety of the KLOX BioPhotonic System in Diabetic Foot Ulcers
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- KLOX Technologies Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of these case series is to evaluate the safety and tolerability of the KLOX BioPhotonic System as adjunctive therapy to Standard Of Care (SOC) in patients with diabetic foot ulcers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | KLOX BioPhotonic System | KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 24 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for diabetic foot ulcers. |
Timeline
- Start date
- 2013-04-01
- Primary completion
- 2016-02-01
- First posted
- 2014-08-21
- Last updated
- 2016-09-05
Locations
3 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT02222506. Inclusion in this directory is not an endorsement.